MktsMarkets

Scinai Immunotherapeutics Ltd.
NASDAQ: SCNIKey statistics
SCNI News
Stories mentioning SCNI from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '23Mar 31 | Q1 '22Mar 31 |
|---|---|---|
| Income Statement | ||
| Revenue | ||
| Cost of Goods Sold | ||
| Gross Profit | 0.00 | 0.00 |
| Operating Expenses | ||
| Research & Development | 1,995 | 1,163 |
| Sales General & Admin | ||
| Total Operating Expenses | ||
| Operating Income (Loss) | (3,186) | (2,615) |
| Interest Income | ||
| Interest Expense | ||
| Other Expense | ||
| Pretax Income | ||
| Tax Provision | ||
| Net Income (Loss) | (3,515) | (2,475) |
| Earnings Per Share (Basic) | (0.00) | (0.00) |
| Earnings Per Share (Diluted) | (0.00) | (0.00) |
| Weighted Average Shares Outstanding (Basic) | 1,295,257 | 744,711 |
| Weighted Average Shares Outstanding (Diluted) | 1,295,257 | 744,711 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SCNI
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a stock listed on the Nasdaq Stock Market under the ticker symbol SCNI. It last traded at $0.4000 (Nov 16, 2026, 4:00 PM ET), up 1.0% on the day. That gives Scinai Immunotherapeutics a market capitalisation of $541.3K.
Over the past 52 weeks SCNI has traded between $0.3900 and $13.00.
For the quarter ended Mar 31, 2023 it reported a net loss of $3.5M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2023 | — | -$3.5M |
| Mar 31, 2022 | — | -$2.5M |
From Scinai Immunotherapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…